dc.contributor.author | Dawson, Jesse | |
dc.contributor.author | Robertson, Michele | |
dc.contributor.author | Dickie, David Alexander | |
dc.contributor.author | Bath, Phillip | |
dc.contributor.author | Forbes, Kirsten | |
dc.contributor.author | Quinn, Terence | |
dc.contributor.author | Broomfield, Niall M. | |
dc.contributor.author | Dani, Krishna | |
dc.contributor.author | Doney, Alex | |
dc.contributor.author | Houston, Graeme | |
dc.contributor.author | Lees, Kennedy R. | |
dc.contributor.author | Muir, Keith W. | |
dc.contributor.author | Struthers, Allan | |
dc.contributor.author | Walters, Matthew | |
dc.contributor.author | Barber, Mark | |
dc.contributor.author | Bhalla, Ajay | |
dc.contributor.author | Cameron, Alan | |
dc.contributor.author | Dyker, Alexander | |
dc.contributor.author | Guyler, Paul | |
dc.contributor.author | Hassan, Ahamad | |
dc.contributor.author | Kearney, Mark T. | |
dc.contributor.author | Keegan, Breffni | |
dc.contributor.author | Lakshmanan, Sekaran | |
dc.contributor.author | Macleod, Mary Joan | |
dc.contributor.author | Randall, Marc | |
dc.contributor.author | Shaw, Louise | |
dc.contributor.author | Subramanian, Ganesh | |
dc.contributor.author | Werring, David | |
dc.contributor.author | McConnachie, Alex | |
dc.date.accessioned | 2023-02-20T11:34:01Z | |
dc.date.available | 2023-02-20T11:34:01Z | |
dc.date.issued | 2023-03-01 | |
dc.identifier.citation | Dawson , J , Robertson , M , Dickie , D A , Bath , P , Forbes , K , Quinn , T , Broomfield , N M , Dani , K , Doney , A , Houston , G , Lees , K R , Muir , K W , Struthers , A , Walters , M , Barber , M , Bhalla , A , Cameron , A , Dyker , A , Guyler , P , Hassan , A , Kearney , M T , Keegan , B , Lakshmanan , S , Macleod , M J , Randall , M , Shaw , L , Subramanian , G , Werring , D & McConnachie , A 2023 , ' Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial ' , EClinicalMedicine , vol. 57 , 101863 . https://doi.org/10.1016/j.eclinm.2023.101863 | en |
dc.identifier.issn | 2589-5370 | |
dc.identifier.other | PURE: 228431119 | |
dc.identifier.other | PURE UUID: efdc5163-d982-456a-8146-bcb6521bc353 | |
dc.identifier.other | RIS: urn:F198F7588192254F912BD60537171CE7 | |
dc.identifier.other | ORCID: /0000-0003-2115-8184/work/129409185 | |
dc.identifier.other | Scopus: 85148380352 | |
dc.identifier.other | PubMed: 36864979 | |
dc.identifier.uri | https://hdl.handle.net/2164/20110 | |
dc.description | Acknowledgments This work was supported by the Stroke Association and British Heart Foundation [grant number TSA BHF 2013/01]. The work of Dr David Dickie and Dr Terry Quinn is funded by the Stroke Association. We would like to thank Christine McAlpine, Ruth Graham, Glasgow Royal Infirmary, UK; Lauren Pearce, Royal United Hospital, UK; Caroline Fornolles, Louise Tate, Frances Justin, Luton and Dunstable University Hospital, UK; Dean Waugh, Leeds Teaching Hospitals NHS Trust, UK; Donal Concannon, Altnagelvin Hospital, UK; Sharon Tysoe, Nina Francia, Nisha Menon, Raji Prabakaran, Southend University Hospital, UK; Amy Ashton, Caroline Watchurst, Marilena Marinescu, Sabaa Obarey, Scheherazade Feerick, University College London NHS Foundation Trust, UK; and Janice Irvine, Sandra Williams, and German Guzman Gutierrez, Aberdeen Royal Infirmary, UK; Caroline Fox and Joanne Topliffe, Broomfield Hospital, Essex, UK. | en |
dc.format.extent | 10 | |
dc.language.iso | eng | |
dc.relation.ispartof | EClinicalMedicine | en |
dc.rights | Copyright © 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en |
dc.subject | Stroke | en |
dc.subject | Allopurinol | en |
dc.subject | Hypertension | en |
dc.subject | White matter hyperintensities | en |
dc.subject | R Medicine | en |
dc.subject | British Heart Foundation | en |
dc.subject | TSA BHF 2013/01 | en |
dc.subject | Supplementary Data | en |
dc.subject.lcc | R | en |
dc.title | Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Centre for Health Data Science | en |
dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
dc.contributor.institution | University of Aberdeen.Medical Sciences - Cardiovascular Group | en |
dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Publisher PDF | en |
dc.identifier.doi | https://doi.org/10.1016/j.eclinm.2023.101863 | |
dc.identifier.vol | 57 | en |